KALV FINANCIAL STATEMENTS

Kalvista Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

KALVKalvista Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q2 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue143.1 M $—

Gross Profit132 M $—

Operating Income-117.4 M $—

EBITDA-74.9 M $—

Net Income-112.4 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
KALV	—	92.2%	-52.4%	-78.6%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
CSL	4.8%	48.6%	32.8%	9.2%
RTALB	24.0%	35.1%	9.0%	136.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
KALV	—	92.2%	-52.4%	-78.6%
MNKD	21.2%	76.0%	7.6%	-6.6%
OLMA	-100.0%	—	—	—
ARDX	18.2%	91.9%	-6.0%	-13.6%
VIR	214.0%	275.2%	-669.6%	-676.0%
WVE	-31.6%	93.8%	-243.2%	-255.7%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q2 2026

Current Liabilities57.4 M $17%
Long-term Liabilities280.7 M $83%

Key Figures

YoY change

Total Assets335.4 M $+33.7%

Total Liabilities338.1 M $+117.6%

Total Equity-2.7 M $-102.8%

Cash & ST Investments300.2 M $+60.0%

Total Debt284.2 M $+4,406.2%

Net Debt54.9 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
KALV	5.58	-10,483.5%	0.21	-0.8%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
CSL	2.57	67.4%	2.22	49.2%
RTALB	1.21	1.2%	0.90	84.9%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
KALV	5.58	-10,483.5%	0.21	-0.8%
MNKD	1.87	-737.7%	10.99	-8.0%
OLMA	10.88	0.2%	2.73	90.5%
ARDX	3.49	140.1%	1.17	29.5%
VIR	7.11	11.8%	0.86	79.2%
WVE	11.26	3.1%	3.03	87.7%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q2 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-38 M $—

Capital Expenditures770 K $+27.1%

Free Cash Flow-38.5 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
KALV	-26.6%	-26.9%	0.5%	33.8%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
CSL	24.0%	20.3%	3.7%	261.5%
RTALB	58.5%	88.6%	10.8%	42.9%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
KALV	-26.6%	-26.9%	0.5%	33.8%
MNKD	5.2%	3.5%	1.7%	-78.8%
OLMA	—	—	—	80.3%
ARDX	-8.5%	-8.8%	0.3%	62.5%
VIR	-681.0%	-679.2%	11.8%	100.8%
WVE	-254.0%	-255.4%	1.4%	99.3%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on KALV

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jun 12, 26. This content is for informational purposes only and is not investment advice.